Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia

Leuk Lymphoma. 2009 Oct;50(10):1564-5. doi: 10.1080/10428190903216853.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Benzamides
  • Benzylamines
  • Bone Marrow / pathology
  • Cell Adhesion / drug effects
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / enzymology
  • Cell Line, Tumor / pathology
  • Chemokine CXCL12 / antagonists & inhibitors*
  • Cyclams
  • Drug Resistance, Neoplasm / drug effects
  • Heterocyclic Compounds / pharmacology
  • Heterocyclic Compounds / therapeutic use*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Piperazines / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Pyrimidines / pharmacology
  • Receptors, CXCR4 / antagonists & inhibitors*
  • Receptors, CXCR4 / chemistry
  • Secondary Prevention
  • Stromal Cells / pathology

Substances

  • Antiviral Agents
  • Benzamides
  • Benzylamines
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Cyclams
  • Heterocyclic Compounds
  • Neoplasm Proteins
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, CXCR4
  • Imatinib Mesylate
  • nilotinib
  • plerixafor